Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ainos, Inc. (AIMD)

Ainos grants BioPhoenix exclusive worldwide VELDONA license; $600,000 initial fee due

Neutral Impact 3 of 5 product/contract Written later

Ainos entered into a Global Exclusive License Agreement with BioPhoenix Co., Ltd. dated September 24, 2026, covering its VELDONA low-dose oral interferon alpha platform for Sjögren's Disease and Thrombocytopenia. BioPhoenix will pay a $600,000 upfront fee and receives a 25% share of Ainos' net sublicensing revenue for these indications, with BioPhoenix funding the clinical and regulatory work. Ainos also agreed not to compete with the licensed indications during the term and for 10 years afterward.

Key points

  • Upfront license fee of $600,000, due after BioPhoenix receives the complete data package and written confirmation that technology transfer is complete
  • Total license fees would be approximately $10.0 million if BioPhoenix licenses all additional VELDONA indications, including the first sublicense fee
  • Ainos receives 25% of BioPhoenix's net sublicensing revenue for the Licensed Indications
  • Agreement runs until the later of patent expiration or 20 years after September 24, 2026, and Ainos may not compete for 10 years after it ends

The filing

CompanyAinos, Inc. (AIMD)
Form8-K, current report
Filed with the SECSep 28, 2026, 8:00 AM ET
Accession number0001493152-26-044454

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.